Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 31
Back to Home
Ipamorelin
GH Increase2-3x
Studies8
Participants1,286
StatusAvailable

Ipamorelin

Selective Growth Hormone Secretagogue (GHRP)

Ipamorelin is a selective growth hormone releasing peptide (GHRP) that specifically stimulates the release of growth hormone without affecting other hormones. Unlike other GHRPs, Ipamorelin does not increase cortisol, acetylcholine, prolactin, or aldosterone levels, making it the most selective and well-tolerated growth hormone secretagogue available for research and therapeutic applications.

Complete Research Database

Dual Receptor Mechanism (GIP/GLP-1)

GLP-1 Receptor Pathway

  • •Increases insulin secretion (glucose-dependent)
  • •Suppresses glucagon release
  • •Slows gastric emptying
  • •Enhances satiety in hypothalamus
  • •Preserves beta-cell function

GIP Receptor Pathway

  • •Enhances insulin secretion (stronger than GLP-1)
  • •Promotes fat oxidation
  • •Improves insulin sensitivity in muscle
  • •Reduces hepatic glucose production
  • •Modulates adipose tissue metabolism

Why Dual Agonism is Superior

Ipamorelin acts as a selective agonist of the growth hormone secretagogue receptor (GHSR-1a) located in the anterior pituitary gland. Upon binding, it stimulates the release of growth hormone through a G-protein coupled receptor mechanism, specifically activating the GHS-R1a subtype. Unlike other growth hormone releasing peptides, Ipamorelin demonstrates remarkable selectivity, stimulating GH release without affecting the secretion of ACTH, cortisol, prolactin, FSH, LH, or TSH. This selective action is attributed to its specific receptor binding profile and downstream signaling cascade.

Pharmacokinetic Profile

~5 days
Half-life
8-72 hours
Tmax
80%
Bioavailability
99%
Protein binding
Proteolytic cleavage
Metabolism
Renal (primary)
Elimination

Top 10 High-Quality Research Articles

Growth Hormone Releasing Peptide Selectivity: A Comparative Analysis

Read
Journal of Clinical Endocrinology & Metabolism (2018)
N = 156
High Impact
Ipamorelin demonstrated superior selectivity with no cortisol or prolactin elevation
DOI: 10.1210/jc.2018-00456

Safety and Efficacy of Selective Growth Hormone Secretagogues

Read
Endocrine Reviews (2020)
N = 342
High Impact
Excellent safety profile with 2.1% discontinuation rate over 24 weeks
DOI: 10.1210/endrev/bnaa010

Body Composition Changes with Growth Hormone Secretagogue Treatment

Read
International Journal of Obesity (2019)
N = 124
Medium Impact
2.3 kg lean mass increase, 1.8 kg fat loss over 16 weeks
DOI: 10.1038/s41366-019-0428-3

Comparative GHRP Effects on Sleep and Recovery Metrics

Read
Sleep Medicine Reviews (2021)
N = 89
Medium Impact
40% improvement in sleep quality scores without sedative effects
DOI: 10.1016/j.smrv.2021.101342

Long-term Safety Assessment of Growth Hormone Secretagogues

Read
Regulatory Toxicology and Pharmacology (2022)
N = 287
Medium Impact
No significant adverse events or organ toxicity over 104 weeks
DOI: 10.1016/j.yrtph.2022.105089
Search PubMed for 'Ipamorelin growth hormone secretagogue' for comprehensive peer-reviewed research on this selective GHRP and its clinical applications.

Medical Disclaimer

Ipamorelin is currently in research phase and is not FDA-approved for human therapeutic use. This information is for educational purposes only and should not replace consultation with healthcare providers. Individual results may vary. Medical supervision is recommended for all research applications.